Biocon Q2 net profit falls 57.3%to ₹56.7 cr

What happened

Biocon reported consolidated net profit of ₹56.7 crore for the September quarter of FY27, compared with ₹132.8 crore a year earlier. Total income rose to ₹4,423.4 crore, while total expenses increased to ₹4,361.9 crore.

Confirmed

Global impact / market context

Profit fell sharply even as income edged higher, while expenses rose faster, indicating that higher costs absorbed much of the additional income. If that pattern persists, it could limit cash available for investment and reduce the benefit Biocon gets from revenue growth.

Analyst inference

The company cited biosimilar progress, a planned European Pertuzumab launch, expanded insulin manufacturing capacity in Malaysia for US demand, and early US momentum for Yesafili and Yesintek. These initiatives may support growth, but the reported quarter shows weaker profit despite slightly higher income.

Analyst inference

What to watch

1. Watch whether Biocon’s next results show expenses growing more slowly than income; that would indicate whether the recent profit decline is easing. Analyst inference
2. Track the upcoming European launch of Pertuzumab, which Biocon’s chairperson described as part of the company’s plans for stronger second-half growth. Proposed
3. Watch whether expanded insulin manufacturing capacity in Malaysia supports US demand, and whether early US momentum for Yesafili and Yesintek continues. Analyst inference

Evidence

• Original source link unavailable